StockData
Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN) stock

LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.33−0.04 (-9.78%)

Close on Nov 18, 2026Market cap $4.21MP/E –Yield –

Lantern Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Lantern Pharma's operating income for the twelve months ending Sep 30, 2026 was -$16.49M. For fiscal 2025 it was -$17.98M. The highest annual figure on record is -$12.59M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$17.98M–
FY2024Dec 31, 2024-$22.22M–
FY2023Dec 31, 2023-$17.88M–
FY2022Dec 31, 2022-$14.43M–
FY2021Dec 31, 2021-$12.59M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$5.38M–
Q2 FY2026Jun 30, 2026-$3.51M–
Q1 FY2026Mar 31, 2026-$3.41M–
Q4 FY2025Dec 31, 2025-$4.20M–
Q3 FY2025Sep 30, 2025-$4.35M–
Q2 FY2025Jun 30, 2025-$4.65M–
Q1 FY2025Mar 31, 2025-$4.77M–
Q4 FY2024Dec 31, 2024-$5.90M–
Q3 FY2024Sep 30, 2024-$5.18M–
Q2 FY2024Jun 30, 2024-$5.41M–
Q1 FY2024Mar 31, 2024-$5.73M–
Q4 FY2023Dec 31, 2023-$4.88M–
Q3 FY2023Sep 30, 2023-$3.52M–
Q2 FY2023Jun 30, 2023-$5.19M–
Q1 FY2023Mar 31, 2023-$4.29M–
Q4 FY2022Dec 31, 2022-$3.83M–
Q3 FY2022Sep 30, 2022-$2.15M–
Q2 FY2022Jun 30, 2022-$4.39M–
Q1 FY2022Mar 31, 2022-$4.07M–
Q4 FY2021Dec 31, 2021-$3.51M–
Q3 FY2021Sep 30, 2021-$4.15M–
Q2 FY2021Jun 30, 2021-$2.48M–
Q3 FY2020Sep 30, 2020-$1.70M–
Q2 FY2020Jun 30, 2020-$833.42K–

More Lantern Pharma figures

See a number that looks wrong?